title: Current Strategy for the Treatment of Ovarian Germ Cell Tumors: Role of Extensive Surgery.
abstract: The necessity and extent of comprehensive surgical staging (CSS) and lymphadenectomy in the treatment of malignant ovarian germ cell tumors (MOGCTs) is still controversial. However, it is uniformly agreed that CSS with lymphadenectomy is crucial to follow up patients without adjuvant chemotherapy in stage I MOGCTs. Considering the chemotherapy-sensitive nature of MOGCTs, fertility-sparing cytoreductive surgery (FSCS) seems a reasonable approach in initial treatment for patients with advanced stage. When encountered with bilateral MOGCTs, debulking is surely granted if there is no desire for fertility. Both ovaries completely replaced by neoplastic tissue composed the most challenging situation especially when patients require childbearing potential. In dysgerminoma histology, which usually has good prognosis, residual disease could be left to spare fertility. USO of the largest and more heterogeneous ovarian mass and a biopsy of the contralateral lesion may be considered if the patients are compliant to regular follow-up. NACT followed by interval FSCS may be a reasonable option in patients with extensive disease, when initial debulking is not an option or where the poor general condition or clinical findings suggest an increased risk of surgical morbidity or preclude fertility-sparing surgery. This is currently not the standard of care but deserves future study. In some rare situation, when any remaining ovarian tissue means high risk, BSO may be performed with the uterus preserved for possible assisted reproduction with donor egg. Treatment failure occurs in a small group of MOGCTs after primary treatment. A good number of recurrences can be salvaged with selected salvage surgery, especially when optimal secondary cytoreduction can be achieved. Immature teratoma is a subtype of MOGCTs where secondary cytoreduction may have a strong role to play.
authors.affiliation: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai, China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
authors.forename: Jin
authors.initials: J
authors.lastname: Li
authors.affiliation: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, 270 Dongan Road, Shanghai, China. wu.xh@fudan.edu.cn.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. wu.xh@fudan.edu.cn.
authors.forename: Xiaohua
authors.initials: X
authors.lastname: Wu
mesh_terms: D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D065426:Cytoreduction Surgical Procedures; D019468:Disease Management; D005260:Female; D013509:Gynecologic Surgical Procedures; D006801:Humans; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000175:diagnosis / Q000601:surgery / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000601:surgery / Q000628:therapy*; D016879:Salvage Therapy; D016896:Treatment Outcome; D047368:Tumor Burden
keywords: Bilateral salpingo-oophorectomy (BSO); Complete remission (CR); Comprehensive surgical staging (CSS); Cytoreduction; Cytoreductive surgery; Debulking surgery; Endodermal sinus tumor (EST); Extensive surgery; Fertility-sparing cytoreductive surgery (FSCS); Fertility-sparing surgery; Immature teratoma (IMT); Lymphadenectomy; Malignant ovarian germ cell tumors (MOGCTs); Neoadjuvant chemotherapy (NACT); Salvage surgery; Unilateral salpingo-oophorectomy (USO)